Extendicare Inc.

OTCPK:EXET.F Stock Report

Market Cap: US$619.8m

Extendicare Valuation

Is EXET.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EXET.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EXET.F ($7.4) is trading above our estimate of fair value ($1.19)

Significantly Below Fair Value: EXET.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EXET.F?

Key metric: As EXET.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EXET.F. This is calculated by dividing EXET.F's market cap by their current earnings.
What is EXET.F's PE Ratio?
PE Ratio13.6x
EarningsCA$63.90m
Market CapCA$866.39m

Price to Earnings Ratio vs Peers

How does EXET.F's PE Ratio compare to its peers?

The above table shows the PE ratio for EXET.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.3x
USPH U.S. Physical Therapy
104.7x29.4%US$1.5b
NHC National HealthCare
15.7xn/aUS$2.0b
ARDT Ardent Health Partners
24.6x38.5%US$2.3b
CON Concentra Group Holdings Parent
16.1x4.0%US$2.8b
EXET.F Extendicare
13.6xn/aUS$866.4m

Price-To-Earnings vs Peers: EXET.F is good value based on its Price-To-Earnings Ratio (13.6x) compared to the peer average (40.3x).

Price to Earnings Ratio vs Industry

How does EXET.F's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.5xn/aUS$41.27m
IDXG Interpace Biosciences
2.4xn/aUS$11.72m
FZMD Fuse Medical
1.1xn/aUS$4.57m
No more companies available in this PE range
EXET.F 13.6xIndustry Avg. 24.6xNo. of Companies11PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EXET.F is good value based on its Price-To-Earnings Ratio (13.6x) compared to the US Healthcare industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is EXET.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EXET.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EXET.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EXET.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.40
US$7.47
+1.0%
7.8%US$8.18US$6.76n/a3
Nov ’25US$6.55
US$7.15
+9.2%
2.4%US$7.40US$7.03n/a3
Oct ’25US$7.00
US$7.15
+2.2%
2.4%US$7.40US$7.03n/a3
Sep ’25US$6.42
US$6.94
+8.1%
4.3%US$7.31US$6.58n/a3
Aug ’25US$5.74
US$6.09
+6.1%
2.8%US$6.21US$5.84n/a3
Jul ’25US$5.42
US$6.12
+12.9%
2.8%US$6.24US$5.87n/a3
Jun ’25US$5.44
US$6.12
+12.4%
2.8%US$6.24US$5.87n/a3
May ’25US$5.32
US$5.93
+11.5%
5.1%US$6.30US$5.56n/a3
Apr ’25US$5.68
US$5.93
+4.5%
5.1%US$6.30US$5.56n/a3
Mar ’25US$5.02
US$5.44
+8.3%
2.8%US$5.62US$5.25n/a3
Feb ’25US$5.29
US$5.44
+2.8%
2.8%US$5.62US$5.25n/a3
Jan ’25US$5.49
US$5.44
-1.0%
2.8%US$5.62US$5.25n/a3
Dec ’24US$5.14
US$5.13
-0.2%
6.0%US$5.43US$4.71n/a3
Nov ’24US$4.10
US$5.06
+23.4%
5.8%US$5.42US$4.70US$6.553
Oct ’24US$4.50
US$5.38
+19.7%
3.4%US$5.57US$5.20US$7.004
Sep ’24US$4.82
US$5.38
+11.8%
3.4%US$5.57US$5.20US$6.424
Aug ’24US$5.35
US$5.50
+2.7%
3.4%US$5.69US$5.31US$5.744
Jul ’24US$5.39
US$5.42
+0.5%
3.4%US$5.60US$5.23US$5.424
Jun ’24US$5.32
US$5.42
+1.8%
3.4%US$5.60US$5.23US$5.444
Mar ’24US$4.75
US$5.32
+12.0%
3.0%US$5.60US$5.23US$5.024
Feb ’24US$4.96
US$5.32
+7.3%
3.0%US$5.60US$5.23US$5.294
Jan ’24US$4.82
US$5.44
+12.9%
3.4%US$5.63US$5.25US$5.494
Dec ’23US$5.05
US$5.44
+7.7%
3.4%US$5.63US$5.25US$5.144
Nov ’23US$5.15
US$5.58
+8.3%
4.9%US$5.90US$5.16US$4.104

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

7D

18.8%

1Y

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

16.2%

1Y

99.5%